| Differential impact of tamoxifen and aromatase inhibitors on thrombin generation: the prospective HEMOBREAST cohort | Blood advances |  | | 2022 | 292 | 647 |
|
| Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab | Gynecologic Oncology Reports | | | 2021 | 268 | 154 |
|
| Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss | Cancer Biology and Therapy | | | 2020 | 359 | 221 |
|
